Eisai is seeking approval for an injectable version of Leqembi while Eli Lilly is developing a new injectable drug. These ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report ... forthcoming Phase 3 clinical trials for Orfoglipron.

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

Eli Lilly has followed through on its plan to file for approval of its Alzheimer's disease candidate donanemab, and is planning to take on Biogen and Eisai with a head-to-head trial against their ...

Eli Lilly's Q4 FY24 guidance adjustment is due ... the commercial potential for donanemab in the treatment of Alzheimer's disease. Looking ahead, the company is progressing with retatrutide ...

with the most planned clinical trials for 2025 are for solid tumours, followed by pain, as per the report. "Eli Lilly targets Scorpion Therapeutics to expand reach in oncology" was originally ...

Older studies estimated a lower risk of dementia. According to new research, the number of people living with the disease in the U.S. is expected to double by 2060.

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the most valuable healthcare stocks in the world, largely due to their successful diabetes and weight loss medications. They are also ...

Eli Lilly's stock price finished Jan. 16 down ... grow past $2 billion annually in a few years. Last July, Lilly's Alzheimer's disease candidate Kisunla earned approval from the FDA to treat ...